Data gathered: December 4
AI Stock Analysis - Cytokinetics (CYTK)
Analysis generated January 3, 2024. Powered by Chat GPT.
Cytokinetics is a biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule drugs designed to enhance muscle function for the potential treatment of serious diseases and medical conditions. Leveraging its deep knowledge of muscle biology and proprietary drug development platform, Cytokinetics is advancing a rich pipeline of potential first-in-class muscle activators as new therapeutic candidates for diseases such as heart failure and amyotrophic lateral sclerosis (ALS).
Stock Alerts - Cytokinetics (CYTK)
 |
Cytokinetics | December 3 Insider Alert: Blum Robert I is continuing selling shares |
|
Cytokinetics | November 27 Insider Alert: Malik Fady Ibraham is selling shares |
|
Cytokinetics | November 26 Business Outlook among employees is down by 8.6% over the last month. |
|
Cytokinetics | November 20 Insider Alert: Blum Robert I is selling shares |
Alternative Data for Cytokinetics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 47 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| Patents | 58 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 649 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,034 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,795 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 458 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 53 | Sign up | Sign up | Sign up |
| Linkedin Employees | 539 | Sign up | Sign up | Sign up |
About Cytokinetics
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
| Price | $50.44 |
| Target Price | Sign up |
| Volume | 1,040,000 |
| Market Cap | $5.98B |
| Year Range | $47.67 - $75.05 |
| Dividend Yield | 0% |
| Analyst Rating | 79% buy |
| Industry | Biotechnology |
In the news
 |
HC Wainwright Reiterates Buy Rating for Cytokinetics (NASDAQ:CYTK)December 4 - ETF Daily News |
|
Needham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)December 4 - ETF Daily News |
 |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3 - Yahoo |
 |
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionDecember 3 - Investing.com |
 |
FDA Accepts Cytokinetics' Application for Cardiovascular DrugDecember 3 - Yahoo |
|
The Manufacturers Life Insurance Company Buys 41,057 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)December 3 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 460,000 | 57M | -56M | -161M | -138M | -1.360 |
| Q2 '24 | 250,000 | 51M | -51M | -143M | -128M | -1.310 |
| Q1 '24 | 840,000 | 46M | -52M | -136M | -124M | -1.330 |
| Q4 '23 | 1.7M | 44M | -50M | -137M | -121M | -1.380 |
| Q3 '23 | 380,000 | 40M | -47M | -129M | -115M | -1.350 |
Insider Transactions View All
| Blum Robert I filed to sell 397,678 shares at $50.8. December 2 '24 |
| Malik Fady Ibraham filed to sell 111,878 shares at $50.1. November 26 '24 |
| Malik Fady Ibraham filed to sell 113,878 shares at $50.2. November 26 '24 |
| WIERENGA WENDALL filed to sell 24,559 shares at $50. November 26 '24 |
| Blum Robert I filed to sell 397,456 shares at $50.6. November 19 '24 |
Similar companies
Read more about Cytokinetics (CYTK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Cytokinetics?
The Market Cap of Cytokinetics is $5.98B.
What is the current stock price of Cytokinetics?
Currently, the price of one share of Cytokinetics stock is $50.44.
How can I analyze the CYTK stock price chart for investment decisions?
The CYTK stock price chart above provides a comprehensive visual representation of Cytokinetics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cytokinetics shares. Our platform offers an up-to-date CYTK stock price chart, along with technical data analysis and alternative data insights.
Does CYTK offer dividends to its shareholders?
As of our latest update, Cytokinetics (CYTK) does not offer dividends to its shareholders. Investors interested in Cytokinetics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cytokinetics?
Some of the similar stocks of Cytokinetics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.